Antibiotics have highly increased human life expectancy. However, multidrug-resistance has become a common problem and conventional antibiotics are becoming increasingly ineffective owing to their unbridled use. Although medicine urgently requires new drugs, hardly any new agent candidates are being developed, as the quest for new substances is economically unattractive for pharmaceutical companies.
DZIF scientists in the research area “Novel Antibiotics” intend to bridge the gap between basic research and current drug development activities in the industry. They are involved in screening new agents and developing methods for treating multidrug-resistant pathogens effectively.